Wednesday, 05 June 2019 11:28

Prati-Donaduzzi plans an increase in the generic drug portfolio

Prati-Donaduzzi (1).jpg

Currently, Prati-Donaduzzi has in its portfolio 290 presentations of generic drugs that represent 96.34% of the company's revenues

Law No. 9,787 of February 10, 1999, which established the regulation of generic drugs in Brazil, completed 20 years. Its creation completely changed the population's access to health. According to a survey by PróGenéricos, since they emerged in the country, these products have brought an estimated savings of over R$ 127 billion to consumers.

Thinking of contributing to improve Brazilians´s health, Prati-Donaduzzi, the pharmaceutical industry that produces the most generic drugs in Brazil, this year plans to launch 175 drug presentations, of which 163 are generic drugs. Of this total, 26 have already been released. Most of the new products will be used to treat areas of the central nervous system, cardiovascular system and metabolic digestive system. In 2018, the company launched 37 presentations, of which 33 are generic drugs.

According to Eder Fernando Maffissoni, Prati-Donaduzzi CEO, the growth of this segment is due to the expansion of the population's access to generic drugs, which cost at least 35% less than the reference ones available in the market. "It is important to consider that the increase in life expectancy directly interferes with the increase in drug consumption. In order to get a better view, only in 2018, Prati-Donaduzzi produced 11.5 billion doses. "

This year, Prati-Donaduzzi will work on two fronts: consolidate the generic drug portfolio with the launch of new presentations and expand the Research and Development area with innovations. The company expects to grow 15% in revenues over the last year and aims to double it over the next five years. "This same percentage prevails regarding the productive capacity. We estimate a number of investments in the improvement of our processes and personnel, which will guarantee us greater productivity gains and new technologies", explains Maffissoni.

Currently, Prati-Donaduzzi has in its portfolio 290 presentations of generic drugs that represent 96.34% of the company's revenues. "We understand that it is a great responsibility to bring health to Brazilians, so our focus is always on the quality of processes and medicines. We are constantly investing in research, technology and equipment - factors that, along with people who dedicate themselves daily to excellence, make us one of the largest portfolios of generic drugs in Brazil", says Maffissoni. 

PRATI-DONADUZZI

Prati-Donaduzzi, a completely domestic pharmaceutical industry, specialized in the development and production of generic drugs. Based in Toledo, western Paraná, Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year and has more than 4,300 employees. The company has one of the largest portfolios of generic drugs in Brazil and aims to grow its sales and production capacity by 15% in 2019.

 *IQVIA MAT MARÇO/2019 PMB + NRC Doses Terapêuticas

 

Read 112 times Last modified on Wednesday, 05 June 2019 11:32